CureVac (CVAC) Stock Forecast, Price & News

CureVac (NASDAQ:CVAC) Frequently Asked Questions

Is CureVac a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CureVac in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CureVac stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVAC, but not buy additional shares or sell existing shares.
View analyst ratings for CureVac or view top-rated stocks.

When is CureVac's next earnings date?

CureVac is scheduled to release its next quarterly earnings announcement on Thursday, July 28th 2022.
View our earnings forecast for CureVac.

How were CureVac's earnings last quarter?

CureVac (NASDAQ:CVAC) posted its quarterly earnings results on Sunday, November, 29th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($54.37) by $54.13.
View CureVac's earnings history.

What price target have analysts set for CVAC?

6 brokerages have issued twelve-month price objectives for CureVac's stock. Their forecasts range from $20.00 to $123.00. On average, they anticipate CureVac's stock price to reach $53.75 in the next year. This suggests a possible upside of 187.0% from the stock's current price.
View analysts' price targets for CureVac or view top-rated stocks among Wall Street analysts.

Who are CureVac's key executives?

CureVac's management team includes the following people:

• Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M., CEO & Member of Management Board (Age 52, Pay $652.14k)
• Mr. Pierre Kemula B.Sc., MD, CFO & Member of Management Board (Age 47, Pay $634.39k)
• Dr. Igor Splawski M.Sc., Ph.D., Chief Scientific Officer & Member of Management Board (Age 53, Pay $427.61k)
• Dr. Antony Blanc Ph.D., MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board (Age 52, Pay $386.73k)
• Dr. Klaus Edvardsen M.D., Ph.D., Chief Devel. Officer & Member of Management Board
• Mr. Malte Greune Ph.D., COO & Member of Management Board
• Dr. Sarah Fakih, VP Corp. Communications & Investor Relations
• Mr. Thorsten Schuller, Head of Corp. Communications
• Slavica Stevanovic-Heck, Head of HR
• Dr. Patrick Baumhof, Sr. VP of Technology

Who are some of CureVac's key competitors?

Some companies that are related to CureVac include Ono Pharmaceutical (OPHLF), BeiGene (BGNE), Elanco Animal Health (ELAN), Biohaven Pharmaceutical (BHVN), Organon & Co. (OGN), Teva Pharmaceutical Industries (TEVA), Jazz Pharmaceuticals (JAZZ), Grifols (GRFS), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Maravai LifeSciences (MRVI), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS) and Intra-Cellular Therapies (ITCI).
View all of CVAC's competitors.

What other stocks do shareholders of CureVac own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE), AstraZeneca (AZN), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and NIO (NIO).

When did CureVac IPO?

(CVAC) raised $200 million in an initial public offering on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers.

What is CureVac's stock symbol?

CureVac trades on the NASDAQ under the ticker symbol "CVAC."

Who are CureVac's major shareholders?

CureVac's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (2.09%), BlackRock Inc. (1.02%), State Street Corp (0.34%), Goldman Sachs Group Inc. (0.15%), Capital Fund Management S.A. (0.12%) and Group One Trading L.P. (0.00%).

Which institutional investors are selling CureVac stock?

CVAC stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, HAP Trading LLC, Goldman Sachs Group Inc., Group One Trading L.P., Cutler Group LP, Baillie Gifford & Co., ProShare Advisors LLC, and Vanguard Group Inc..

Which institutional investors are buying CureVac stock?

CVAC stock was purchased by a variety of institutional investors in the last quarter, including Capital Fund Management S.A., BlackRock Inc., Citigroup Inc., Invesco Ltd., Martingale Asset Management L P, State Street Corp, Healthcare of Ontario Pension Plan Trust Fund, and Dynamic Technology Lab Private Ltd.

How do I buy shares of CureVac?

Shares of CVAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CureVac's stock price today?

One share of CVAC stock can currently be purchased for approximately $18.73.

How much money does CureVac make?

CureVac has a market capitalization of $3.50 billion and generates $115.57 million in revenue each year.

How many employees does CureVac have?

CureVac employs 455 workers across the globe.

What is CureVac's official website?

The official website for CureVac is www.curevac.com.

How can I contact CureVac?

CureVac's mailing address is PAUL-EHRLICH-STRABE 15 TUBINGEN, BADEN-WURTTEMBERG 2M, 72076. The company can be reached via phone at 49-70-71988-30, via email at [email protected], or via fax at 49-7071-9883.